HIV-1 drug resistance: Can we overcome?

Expert Opinion on Biological Therapy

Volumn 2, Issue 7, 2002, Pages 751-761

  Brenner, Bluma G ^a   Turner, Dan ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antiviral therapy; Drug susceptibility; Genotypic resistant variants; HIV 1 drug resistance; Treatment interruption; Viral fitness

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CROSS RESISTANCE; DISEASE COURSE; DRUG SENSITIVITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MULTIDRUG RESISTANCE; PHENOTYPE; REVIEW; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036795630     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.7.751     Document Type: Review

References (78)

1. Pallela FJ, Delaney KM, Moorman AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. (1998) 338:853-860.
2. Wainberg MA, Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA (1998) 279:1977-1983.
3. Hirsch MS, Conway B, D'Aquila RT et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA (1998) 279:1984-1991.
4. Yeni PG, Hammer SM, Carpenter CJ et al: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 288:222-235.
5. Schinazi RF, Larder B, Mellors JW.: Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Intl. Antiviral News (2000) 8:85-91.
6. Durant J, Clevenburgh P, Halfon P et al.: Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet (1999) 353:2195-2199.
7. van Vaerenbergh K, van Laethem K, van Wijngaerden E et al.: Baseline HIV Type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy. AIDS Res. Hum. Retroviruses (2000) 16:529-537.
8. Clevenbergh P, Durant J, Halfon P et al.: Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antiviral Ther. (2000) 5:65-70.
9. Zolopa AR, Shafer RW, Warford A et al.: HIV-1 genotypic resistance patterns predict response to saquinavir-ritinovir therapy in patients whom previous prortease inhibitor therapy had failed. Ann. Intern. Med. (1999) 131:813-821.
10. Baxter JD, Mayers DL, Wentworth DN et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (2000) 14:F83-93.
11. Lorenzi P, Opravil M, Hirschl B et al.: Impact of drug resistance mutations on virologic response to salvage therapy. AIDS (1999) 13:F17-F21.
12. Meynard Jl, Vray M, Morand-Jouvert L et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial (NARVAL). AIDS (2002) 16:727-736.
13. Degruttola V, Dix L, D'Aquila R et al.: The relation between baseline HIV drug resistance and response to antiretiviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther (2000) 5:41-48.
14. Harrigan PR, Montaner JS, Hogg RS et al.: Baseline resistance profile predicts response to ritinovir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 13:1863-1871.
15. Miller V, Phillips A, Rottman C et al.: Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy. J. Infect. Dis. (1998) 177:1521-1532.
16. Cohen C, Hunt S, Sension M et al.: A randomized trial assessing the impact of phenotypic resistance on antiretroviral therapy. AIDS (2002) 8:579-588.
17. Deeks SG, Hellmann N, Grant RM et al.: Novel four drug salvage treatment regimens after failure of a protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with viriologic outcome. J. Infect. Dis. (1999) 179:1375-1381.
18. Weinstein MC, Goldie SJ, Losina E et al.: Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. (2001) 134:440-450.
19. Call SA, Saag MS, Westfall AO et al.: Phenotypic drug susceptibility testing predicts long-term virologic suppressions better than treatment history alone in patients with human immunodeficiency virus infection. J. Infect. Dis. (2001) 183:401-408.
20. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the panel on clinical practices for treatment of HIV. MMWR (2002) 51(RR-7):1-55.
21. US Public Health Service: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Updated February 4, 2002.
22. The EuroGuidelines Group for HIV Resistance: clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS (2001) 15:309- 320.
23. Vandamme AM, Houyez F, Banheghyi D et al.: Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Ther. (2001) 6:21-40.
24. Little SJ, Holte S, Routy JP et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. (2002) 347:385-394.
25. Katzenstein TL, Jergensen LB, Nielson H et al: Lack of obvious interplay between baseline genotype and virological response among protease- inhibitor-naive patients treated with HAART. Antiviral Ther (1999) 4(Suppl. 1):68 (Abstract 104).
26. Rousseau MN, Vergne L, Montes B et al.: Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J. Acquir. Immune Def. Syndr. (2001) 26:36-43.
27. D'Aquila RT, Schapiro JM, Brunvezinat F et al.: Drug resistance in HIV-1. Drug resistance mutations in HIV-1. Topics in HIV Med. (2002) 10:11-15.
28. Shafer RW, Gonzales MJ, Brunvezinet F: Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antiviral Ther. (2001) 6(Suppl. 1):101.
29. Hammond J, Larder BA, Schinasi RF, Mellors JW: Mutations in retroviral genes associated with drug resistance. (http://www.hiv.lan.gov/HTML/reviews Mellors.html)
30. Beerenwinkel N, Schmidt B, Walter H et al.: Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype Proc. Natl Acad. Sci. (USA) (2002) 99:8271-8276.
31. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral therapy efficacy of AZT-3TC combination therapy. Science (1995) 269:696-699.
32. Wainberg MA, White AJ: Current insights into reverse transcriptase inhibitor-associated resistance. Antiviral Ther. (2001) 6:11-19.
33. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H: Differential phosphorylation of azidothymidine, dideoxycytidine and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. (1993) 91:2326-2333.
34. Lennerstrand J, Stammers DK, Larder BA: Biochemical mechanism of human immunodeficiency virus Type 1 reverse transcriptase resistance to stavudine. Antimicrob. Agents Chemother. (2001) 45:2144-2146.
35. Meyer PR, Matsuura SE, Schinazi RF, Therefore AG, Scott WA: Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2-deoxynucleoside triphosphates. Antimicrob. Agents Chemother. (2000) 44:3465-3472.
36. Romano L, Venturi G, Bloor S et al.: Broad nucleoside-analogue resistance implications for human immunodeficiency virus Type 1 reverse-transcriptase mutations at codon 44 and 118. J. Infect. Dis. (2002) 185:898-904.
37. Loemba H, Brenner B, Parniak MA et al.: Genetic divergence of HIV-1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. (2002) 46:2087-2094.
38. Coffin JM: HIV population dynamics in vivo: implication for genetic variation, pathogenesis and therapy. Science (1995) 267:483-489.
39. Quinones ME, Weber J, Rangel HR, Chakraborty B: HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. (2001) 3:223-242.
40. Schuurman R, Nijhuis M, Leeuwen RV et al.: Rapid changes in human immunodeficiency virus Type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. (1995) 171:1411-1419.
41. Gartland M and Avanti Study Group: AVANTI 3: a randomized, double- blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antiviral Ther. (2001) 6:127-34.
42. Maguire M, Gartland M, Moore S et al.: Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies. AIDS (2000) 14:1195-201.
43. Staszewski S, Hill AM, Bartlett J et al.: Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS (1997) 11:477-483.
44. Back NK, Nijhuis M, Keulen W et al.: Reduced replication of lamivudine-resistance HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. (1996) 15:4040-4049.
45. Descamps D, Flandre P, Calvez V et al.: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege. JAMA (2000) 283:205-211.
46. Vainberg MA, White AJ: Current insights into reverse transcriptase inhibitor-associated resistance. Antiviral Ther. (2001) 6:11-19.
47. Keulen W, van Wijk A, Schuurman R et al.: Increased polymerase fidelity of lamivudine-resistance HIV-1 variants does not limit their evolutionary potential. AIDS (1999) 13:1343-1349.
48. Wainberg MA, Drosopoulos WC, Salomon H et al.: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (1996) 271:1282-1285.
49. Feng JY, Anderson KS: Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the lamivudine-resistance mutant (M184V) of HIV-1 reverse transcriptase. Biochemistry (1999) 38:9440-9448.
50. Gotte M, Wainberg MA: Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resistance Updates (2000) 3:30-38.
51. Salomon H, Wainberg MA, Brenner BG et al.: Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use. AIDS 14:F17-F23.
52. Brenner B, Routy JP, Petrella M et al.: Persistence and fitness of multi-drug resistant human immunodeficiency virus Type 1 acquired in primary infection. J. Virol. (2002) 76:1753-1761.
53. Devereux HL, Youle M, Johnson MA, Loveday C: Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 13:F123-F127.
54. Deeks SG, Wrin T, Liegler T et al.: Virologic and immunologic consequences of discontinuing combination and retroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. (2001) 344:472-480.
55. Verhofstede C, Wanzeele FV, van der Gucht B, de Cabooter N, PLUM J: Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS (1999) 13:2541-2546.
56. Devereux HL, Emery VC, Johnson MA, Loveday C: Replicative fitness in vivo of HIV-1 variants with multiple drug resistance mutations. J. Med. Virol. (2001) 65:218-224.
57. Picchio GR, Valdez H, Sabbe R et al.: Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J. Acquir. Immune Defic. Syndr. (2000) 25:289-295.
58. Frost SD, Nijhuis WM, Schuurman M, Boucher CAB, Leigh-Brown CA: Evolution of lamivudine resistance in human immunodeficiency virus Type 1-infected individuals: the relative roles of drift and selection. J. Virol. (2000) 74:6262-6269.
59. Miller MD, Anton KE, Mulato AS et al.: Human immunodeficiency virus Type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. (1999) 179:92-100.
60. Masqualier B, Descamps D, Carriere I et al.: Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the delta lamivudine roll-over study. Antiviral Ther. (1999) 4:69-77.
61. Gotte M, Li X, Wainberg MA: HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Archiv. Biochem. Biophys. (1999) 365:199-120.
62. Croteau G, Doyon L, Thibeault D et al.: Impaired fitness of human immunodeficiency virus Type 1 variants with high-level resistance to protease inhibitors. J. Virol. (1997) 71:1089-1096.
63. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A: Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication and protein maturation of and retroviral drug-resistant human immunodeficiency virus Type 1. J. Virol. (2001) 75:3291-3300.
64. Quinones-Mateu M, Ball S, Marazon A et al.: A dual infection/ competition assay shows a correlation between ex vivo human immunodeficiency virus Type 1 fitness and disease progression. J. Virol. (2000) 74:9222-9233.
65. Harrigan PR, Bloor S, Larder BA: Relative replicative fitness of zidovudine-resistant human immunodeficiency virus Type 1 isolates in vitro. J. Virol. (1998) 72:3773-3778.
66. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus Type 1. J. Virol. (1999) 73:3744-3752.
67. Marine AFM, Keulen W, Boucher CAB, de Boer RJ: Estimating relative fitness in viral competition experiments. J. Virol. (2000) 74:11067-11072.
68. Lu J, Kuritkes D: A novel recombinant marker virus assay for comparing the relative fitness of HIV-1 reverse transcriptase variants. J. Acquir. Immune Defic. Syndr. (2001) 27:7-13.
69. Miller V: Structured treatment interruptions in and retroviral management of HIV-1. Curr. Opin. Infect. Dis. (2001) 14:29-37.
70. Taffe P, Rickenbach M, Hirschel B et al.: The Swiss HIV cohort study: impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS (2002) 16:747-755.
71. Dybul M: Structured treatment interruption: approaches and risks. Curr. Infect. Dis. Rep. (2002) 4:175-180.
72. Kilby JM, Goepfert PA, Miller AP et al.: Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann. Intern. Med. (2000) 133:435-438.
73. Kijak GH, Simon V, Balfe P et al.: Origin of human immunodeficiency virus Type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. (2002) 76:7000-7009.
74. Izopet J, Souyris C, Hance A et al.: Evolution of human immunodeficiency virus Type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J. Infect. Dis. (2002) 185:1506-1510.
75. Tubiana R, Ghosn J, De-Sa M et al.: Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission. AIDS (2002) 16:1083-84.
76. Albrecht D, Zollner B, Feucht HH et al.: Reappearance of HIV multi-drug resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J. Clin. Virol. (2002) 24:93-98.
77. Hogg RS, Yip B, Chan KJ et al.: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 286:2568-2577.
78. Montaner JS, Harrigan PR, Jahnke N et al.: Multiple drug rescue therapy for HIV-infected individuals with prior virological failure to multiple regimens. AIDS (2001) 15:61-69.